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Abstract
Background: Care-home residents often have multiple cognitive and physical impairments and are at 
high risk of adverse drug events (ADEs). 
Aim: Describe excessive polypharmacy and potentially inappropriate prescribing predisposing care-
home residents to ADEs.
Design and Setting: Cross-sectional analysis of all dispensed prescriptions for residents of 147 care-
homes. 
Method: Prevalence of excessive polypharmacy was examined using multilevel logistic regression, by 
modelling associations between individual and care-home predictors with excessive polypharmacy 
(≥10 drugs). Prescribing of drugs known to increase the risk of eight clinically important ADE 
categories was examined. Drugs prescribed within each ADE category, for each resident, were 
counted.
Results: 32.3% of residents had excessive polypharmacy, which was more common in residents aged 
70-74 years (aOR=1.86 [1.04-3.34]) and 80-84 years (aOR=1.75 [1.01-3.02]), living in a residential 
care-home (aOR=1.50 [95%CI 1.19-1.88]), and located in Fife (aOR=1.37 [1.09-1.71]). Excessive 
polypharmacy was less common in residents with dementia (aOR=0.73 [0.64-0.84]). 8.9% (5.9%-
11.6%) of the variation was attributable to care-home predictors. Potentially inappropriate prescribing 
of ≥2 drugs was seen across all ADE categories with highest prevalence seen in drugs predisposing 
to constipation (35.8%), sedation (27.7%), and renal injury (18.0%). 
Conclusions: Excessive polypharmacy is common in care-home residents and is associated with both 
individual and care-home predictors. Potentially inappropriate prescribing of drugs that predisposed 
residents to all included ADEs categories is common. Research is needed to support and evaluate 
safe care-home prescribing practices. 
Word count: 227
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How this fits in
Care-home residents often have complex care needs due to multiple cognitive and physical 
impairments that put them at increased risk of adverse drug events (ADEs). Several studies refer to 
polypharmacy within care-home residents, but few have examined prescribing systematically 
according to body system, associations between individual and care-home predictors and excessive 
polypharmacy, or potentially inappropriate prescribing patterns predisposing to specific ADEs. 
Our study finds that excessive polypharmacy and potentially inappropriate prescribing of drugs that 
increase risk of ADEs is common in this population. Research is needed to support and evaluate 
care-home prescribing practices, to achieve the optimum balance between symptomatic relief of 
symptoms and provision of long-term preventative therapies for this vulnerable population.  
                               
                             
                     
Introduction
Care-home residents are often frail older adults with complex care needs due to multiple cognitive 
and physical impairments.1 However, the majority of clinical guidance used by clinicians for this 
population is underpinned by clinical trials that usually exclude frail older adults,2 therefore advocating 
silo medicine through optimising single disease treatment.3 Application of these clinical guidelines, by 
multiple prescribers, from different specialties, in different locations, can result in a cascade of 
prescribing over a lifetime that results in polypharmacy, some of which may be due to the treatment of 
avoidable ADEs with more medicines.4 Older adults are vulnerable to ADEs due to age and disease 
related changes in renal, cognitive, and sensory function, altered pharmacokinetics and 
pharmacodynamics,5 making it difficult to distinguish between disease-related symptoms and ADEs.6 
Residents are therefore at risk of polypharmacy and potentially harmful, often preventable, drug-drug 
and drug-disease interactions.3, 7 
Despite its importance, there is no consensus on the definition of polypharmacy. Count definitions are 
common where prescribing of ≥5 and ≥10 different drugs define polypharmacy and excessive 
polypharmacy respectively.7, 8 Other definitions focus on the appropriateness of polypharmacy (where 
all drugs are prescribed for the purpose of achieving specific therapeutic objectives and therapy has 
been optimised to reduce the risk of ADEs), irrespective of count. Polypharmacy is likely inappropriate 
when one or more drugs are prescribed that were never strongly indicated, where the indication has 
expired, or where one or a combination of drugs put the person at an unacceptably high risk of an 
ADE. 
ADEs are estimated to be the primary cause of one in ten hospital admissions in older adults,9 often 
relating ADEs such as cognitive impairment, falls,10 and renal injury.11 There is positive correlation 
between the number of ADE-risk increasing drugs and risk of developing an ADE, for example co-
prescription of psychotropic and cardiovascular medications that predispose to falls.10 Appropriate use 
of medications can increase longevity, reduce hospital admissions, and improve quality of life. 
However, the inappropriate polypharmacy is associated with increased drug costs, use of healthcare 
services, and symptoms that reduce a person’s quality of life.12 The aim of our study is to examine the 
prevalence of excessive polypharmacy and potentially inappropriate prescription of drugs that 
increase risk of ADEs, within a large nationally representative cohort of care-home residents. 
Methods
                               
                             
                     
We performed a cross-sectional analysis of prescribing in all residents aged ≥60 years of care-homes 
for older adults in two UK National Health Service (NHS) health board areas, Tayside and Fife. The 
NHS provides universal health-care coverage for all residents and no fees are required in payment for 
prescribing of medications. Care-home is an umbrella term for long-term care settings in the UK. Both 
residential and nursing care-homes provide 24-hour care and support for adults with a range of 
needs.
Residents were identified by matching each individual’s residential address to Care Inspectorate care-
home registered addresses,13 and characteristics determined from publicly available Care 
Inspectorate data.14 Prescribing records, including all dispensed medications from community 
pharmacies within the study area, were linked with demographic data. Anonymised data were 
provided by the University of Dundee Health Informatics Centre15 and held in the ISO270001 and 
NHS Scotland accredited safe haven. Standard operating procedures have been approved by the 
NHS East of Scotland Research Ethics Committee and Caldicott Guardians who have legal 
responsibility for approving use of unconsented NHS patient data.
Excessive polypharmacy was defined as prescription of ≥10 distinct drug-classes determined by 
subsections of the British National Formulary,16 expanded as necessary to ensure that drug-classes 
contained drugs with distinct mechanisms of action.7 Distinct drugs which are frequently co-prescribed 
(e.g., subsection 2.9 antiplatelet drugs) were expanded. Drugs within combination preparations were 
counted separately (e.g., co-codamol as paracetamol and codeine). Prescriptions for medical 
appliances (e.g., stoma preparations, glucose testing strips), were excluded, avoiding over-counting 
of polypharmacy. “Current” prescribing was defined as any prescription in the 56 days prior to 31st 
March 2017. Repeat prescriptions for care-home residents in these regions are frequently issued in 
28-day cycles. Therefore, inclusion of two prescribing cycles was used to optimise capture of repeat 
prescribing, as well as highly interacting drugs which are not always given daily or issued every 28 
days (e.g., sleeping tablets or analgesics). Individual predictors were age, sex, and dementia status 
which was defined by any prior record of dementia during a hospital admission or any prior 
prescription for a dementia drug (BNF 4.11). Care-home predictors were care-home status (nursing or 
residential), size (small, medium, or large), Risk Assessment Document score (RAD; a risk 
assessment score categorised as low-, medium-, and high-risk; high-risk score correlating with 
prioritised inspections),17 and NHS health board (Tayside or Fife). Deprivation status (Scottish Index 
of Multiple Deprivation [SIMD]) was not analysed because postcode assigned SIMD is a poor marker 
                               
                             
                     
of individual socioeconomic status in this population as care-home residents frequently migrate to 
new areas for care-home placement.
Associations between individual and care-home predictors with excessive polypharmacy were 
examined through multilevel logistic regression with random intercept, accounting statistically for 
clustering within care-homes. Multicollinearity was assessed using chi-squared hypothesis tests 
between categorical variables and generalised variation inflation factor for higher order correlations. 
Variance was partitioned in an empty model to estimate the intra-class correlation coefficient. Final 
independent predictor selection for the adjusted model was guided by minimisation of the Akaike 
Information Criterion and included predictors with significant univariate odds ratios (ORs). Potentially 
inappropriate prescribing of drugs known to increase risk ADEs associated with adverse clinical 
outcomes and/or reduced quality of life in older people was measured. ADE categories included 
anticholinergic effects, bleeding, constipation, heart failure, hypotension, renal injury, sedation, and 
urinary retention. The number of drugs prescribed within each ADE category for each resident was 
counted, then cross-tabulated by age according to drug lists developed through reference to Scottish 
Government Polypharmacy Guidance,18 drug Summary of Product Characteristics (SPC),19 and the 
BNF16 (Appendix 1). Anticholinergic drugs with modified Anticholinergic Risk Score (mARS) of ≥2 
were included.20 Adjusted ORs (aORs) were reported with 95% confidence intervals (CIs) and 
statistical significance of 5%. All statistical analyses and plotting was undertaken using R(v3.2.5).21
Results
Demographics
4468 people aged ≥60 years in NHS Tayside and Fife regions were resident in 147 care-homes for 
older people on 31st March 2017 (Table 1). Mean age of residents was 84.9 years (SD8.1), 3196 
(71.5%) were female, and 2160 (48.3%) had a diagnosis of dementia. 2601(58.2%) residents lived in 
71 care-homes providing nursing care. 3749 (83.9%) of residents lived in 117 privately owned care-
homes. Similar numbers of residents lived in medium and large, rather than small, care-homes (2028 
[45.4%], 1800 [40.3%], and 637 [14.3%] respectively), and the majority lived in care-homes with a 
low-risk RAD score (3039 [68.0%]). Most residents lived in 90 care-homes located in NHS Tayside 
(2676 [59.9%]).
Prescribing
                               
                             
                     
The mean and median number of individual drugs dispensed per person was 7.8 (interquartile range 
[IQR] 3.5–12.1) and 8 (IQR 3-13) respectively for all residents (Table 1, Figure S1).
All residents were prescribed drugs from mean 4.2 (SD1.9) BNF chapters, and residents with 
excessive polypharmacy were prescribed drugs from mean 6.1 (SD1.3). BNF chapters with highest 
prevalence of prescribing were 4-Central Nervous System, 1-Gastrointestinal System, and 2-
Cardiovascular System, with 82.5%, 66.9%, and 64.5% of residents receiving ≥1 drug prescriptions 
respectively (Table 2, Figure S2). Chapters 9-Nutrition and Blood (45%), 13-Skin (39.1%), and 6-
Endocrine System (37.1%) also had high frequency prescribing of ≥1 drug. Chapters with lowest 
frequency of prescribing were 7-Gynaecology & Urinary Tract (9.0%), 12-Ear, Nose and Oropharynx 
(3.0%), and 8-Malignant Disease & Immunosuppression (1.9%). 
The most prescribed drug classes were paracetamol (47.2%), osmotic laxatives (including lactulose 
and macrogols) (36.3%), and proton pump inhibitors (35.8%) (Table 2). Statins (27.3%), drugs for 
dementia (26.4%), emollients (23.1%), and loop diuretics (20.6%) were prescribed in over one fifth of 
residents.
Excessive polypharmacy
Excessive polypharmacy was present in 1444 (32.3%) of residents, in similar proportions of females 
and males (Table 1). Calculation of the ICC in a null model showed that a large amount of the 
variation in excessive polypharmacy was due to differences between care-homes (8.9% [95%CI 
5.9%-11.6%]) (Table 3). 
In the adjusted multilevel model, excessive polypharmacy was more common in residents aged 70-74 
years (aOR=1.86 [1.04-3.34]) and 80-84 years (aOR=1.75 [1.01-3.02]), compared to residents aged 
60-64 years. Residents living in residential care-homes were more likely to have excessive 
polypharmacy than those in nursing care-homes (aOR=1.50 [1.19-1.88]), as were residents living in 
the NHS Fife area (aOR=1.37 [1.09-1.71]) (Table 3, Figure 1). Residents with dementia (aOR0.73 
[0.64-0.84]) and those living in care-homes with medium RAD score (aOR=0.72 [0.52-0.99] versus 
care-homes with low RAD score) were less likely to have excessive polypharmacy. No statistically 
significant differences were found between females and males.
                               
                             
                     
Prescribing of drugs associated with ADEs
Potentially inappropriate prescribing of drugs within all ADE categories was common, ranging of 
17.7% (anticholinergic) to 66.8% (constipation) of residents prescribed ≥2 drugs (Figure 2, Table S1). 
Prescribing of any drugs predisposing to sedation, bleeding, and renal injury was found in 63.6%, 
54.0%, and 51.5% residents respectively. Categories with highest levels of prescribing of ≥2 drugs 
were constipation (35.8%), sedation (27.7%), and renal injury (18.0%). Co-prescribing of the highest 
number of drugs within the same category, ≥4 drugs, was seen in constipation (5.8%) and sedation 
(2.1%).
Older residents had more prescribing predisposing to renal injury and hypotension, and less 
predisposing to sedation and urinary retention (Table S2, Figure S3). Drugs predisposing to 
anticholinergic effects, heart failure, bleeding, and constipation did not show variation by age.
The most prescribed drug classes within the constipation category were loop diuretics (21.1%), 
opiates (20.5%), and beta-blockers (18.0%) (Table S3). Prescribing of drug classes predisposing to 
sedation included opiates (20.5%), selective serotonin-reuptake inhibitors (SSRIs) (19.5%), and beta-
blockers (18.0%). The most prescribed drug classes predisposing to renal injury included loop 
diuretics (21.1%), penicillin antibiotics (11.3%), and angiotensin-converting enzyme inhibitors (10.6%). 
Discussion
Summary
The mean and median number of individual drugs dispensed per person was 7.8 (SD 4.3) and 8 (IQR 
3-13) respectively. Care-home predictors accounted for 8.9% (95%CI 5.9-11.6) of variation in rates of 
excessive polypharmacy. Excessive polypharmacy was more likely in residents living in residential 
care-homes, and those living in NHS Fife.
Highest prescribing rates were seen for drugs relating to the central nervous, gastrointestinal, and 
cardiovascular systems. Prescribing ≥1 drug known to increase the risk of the ADE categories ranged 
from 17.7% (anticholinergic) to 66.8% (constipation). Prescribing of ≥2 drugs ranged from 2.4% 
(anticholinergic) to 35.8% (constipation). Drugs used to manage cardiovascular disease, pain, and 
mental health conditions were most prescribed within the ADE categories.
                               
                             
                     
Strengths and limitations
Strengths of our study include the comprehensive assessment of all dispensed medications for the 
entire population of care-home residents in two health board regions, systematically examining 
prescribing according to body system, and using multilevel analysis to account for clustering of 
residents within many care-homes. Prescriptions for medical appliances were excluded, therefore 
avoiding over-counting of polypharmacy. ADE category drug lists were formulated with reference to 
validated sources.16, 19 Current prescribing was defined as all drugs issued in the last 56 days, 
therefore including recent short courses of medications, which is important as such drugs often have 
important interactions and/or commonly cause adverse events, for example antibiotics and 
analgesics. 
The study has several limitations, including the lack of clinical diagnoses other than dementia status, 
meaning that clinical appropriateness cannot be evaluated (although ‘indication’ in the very frail is not 
straightforward given the lack of evidence in this population). Clinical diagnoses, derived measures of 
multimorbidity and/or frailty and inter-GP practice prescribing practices were not available and would 
be valuable factors to include in further research. 48.3% of residents were identified by routine data 
as having dementia. This figure is lower than the previous estimate of 62% of Scottish long-stay care-
home residents, likely reflecting that dementia in this population is not always coded.22 Additional 
clinical detail could support application of more formal tools such as the STOPP/START23 or Beers 
Criteria24 for potentially inappropriate medication use in older adults. 
Comparison with existing literature
Similar research found that excessive polypharmacy was seen in 24.3% of residents included in the 
Services and Health for Elderly in Long TERm care (SHELTER) study incorporating 57 European 
care-homes.8 Lower prevalence rates in comparison with our study are likely to be related to differing 
length of data capture (three versus 56 days). Despite differing prevalence rates, the SHELTER study 
also found that excessive polypharmacy was less common in residents with dementia. A study from 
Ontario, Canada, analysing a one-year prescribing cross-section from 2005, found that prescribing of 
≥9 drugs was seen in 15.5% of care-home residents.25 This lower prevalence rate may represent a 
true difference in practice between Canada and the UK, although the Canadian study used data from 
12 years before our study, when polypharmacy rates were also lower in the general population in 
                               
                             
                     
Scotland.7 A cross-sectional study from Italy showed that antipsychotics were the most commonly 
prescribed drugs in people with dementia, and PPIs in people without dementia.26 A large study from 
France examined prevalence of prescribing of specific potentially inappropriate drugs in care-home 
residents, finding that psychotropic drugs were the most commonly prescribed drug group.27 These 
studies did not systematically examine prescribing by body system, individual and care-home 
predictors associated polypharmacy, or combination prescribing that might put a person at increased 
risk of ADEs. Studies examining ADEs are less common, and where done tend to examine all older 
people rather than those living within care-homes. One such study of community-dwelling older 
people from the Republic of Ireland looked at patient reported ADEs. 74% of the sample population 
were affected by ADEs, most commonly citing easy bruising, urinary frequency and ankle swelling, 
however did not examine the prescribing patterns associated with these ADEs.28
Implications for research and/or practice
Our findings show that there is a need to evaluate clinical practice in terms of drug prescribing for 
residents, with careful consideration of the relative benefits and harms in the context of the individual. 
GPs are responsible for most prescribing for care-home residents, with specialist care typically being 
episodic during acute events.29 Primary care prescribing support is required, as well as whole 
systems approaches, including all prescribers and technologies, to promote a realistic medicines 
approach in this population. Prescribers require training and support to deliver safe prescribing and 
de-prescribing practices, for all residents including those without dementia, alongside systemic 
changes such as technology appraisal so that safe prescribing is supported from GP information 
technology (IT) systems, provision of appropriate national clinical guidance, and adaptation of 
incentivisation including the Quality Outcomes Framework (QOF) to account for the complexity of 
care requirements for care-home residents. This involves developing an understanding of real-world, 
complex treatment regimens in relation to the clinical context where the risk-benefit balance between 
prescribing or not prescribing can be examined. Secondly, our quantification of the magnitude of 
increased vulnerability to ADEs for residents can be used to inform prescribing practice through 
identification of the most prevalent potentially inappropriate prescribing of drugs associated with 
ADEs.
Several areas of uncertainty would benefit from further research. Not all prescribing or polypharmacy 
is harmful, so it is important to distinguish between appropriate and inappropriate polypharmacy in 
residents. Factors associated with excessive polypharmacy exist at individual and care-home levels, 
and therefore further examination of practices across these levels is needed to identify practices 
                               
                             
                     
associated with excessive polypharmacy. Considerable unexplained variation was found in 
prescribing between care-homes, and research examining issues such as care-home staff tolerance 
of behavioural and psychological symptoms of disease (for example triggering psychotropic 
prescribing in people with dementia) would be useful.30 Further research is needed to identify how 
best to deliver the optimum balance between burden and benefit.
Conclusion
Care-home residents have high rates of excessive polypharmacy that is associated with both 
individual and care-home predictors, and there is likely additional variation by region. Potentially 
inappropriate prescribing of drugs that increase risk of all included ADE categories is common. 
Further research is required to enable bespoke care-home support and provision of medication 
reviews, including safe prescribing and de-prescribing practices, that facilitate balancing the need for 
symptomatic relief of symptoms and long-term preventative therapies, against the potential risks of 
prescribing specific drugs and polypharmacy.
Word count: 2677
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Tables and figures
Table 1. Care-home resident and care-home characteristics
Dispensed 0-9 drugs




 N = 1444 (32.3)
No. (column %)
All residents
N = 4468 (100)
No. (column %)
Sex Male 850 (28.1) 422 (29.2) 1272 (28.5)
Female 2174 (71.9) 1022 (70.8) 3196 (71.5)
Age, years Mean (SD) 85.1 (8.3) 84.6 (7.9) 84.9 (8.1)
Age-group 60-64 68 (2.2) 19 (1.3) 87 (1.9)
65-69 101 (3.3) 53 (3.7) 154 (3.4)
70-74 184 (6.1) 101 (7.0) 285 (6.4)
75-79 317 (10.5) 163 (11.3) 480 (10.7)
80-84 580 (19.2) 302 (20.9) 882 (19.7)
85-89 765 (25.3) 393 (27.2) 1158 (25.9)
90-94 709 (23.4) 288 (19.9) 997 (22.3)
≥95 300 (9.9) 125 (8.7) 425 (9.5)
Drugs prescribed1 Mean (SD) - - 7.8 (4.3)
Median (IQR) - - 8 (5)
Number of BNF chapters 
drugs prescribed from 
Mean (SD) 3.4 (1.5) 6.1 (1.3) 4.2 (1.9)
Dementia diagnosis No dementia 1506 (49.8) 802 (55.5) 2308 (51.7)
Dementia 1518 (50.2) 642 (44.5) 2160 (48.3)
Care-home type Nursing care (71 homes) 1858 (61.4) 743 (51.5) 2601 (58.2)
Residential care (76 homes) 1166 (38.6) 701 (48.5) 1867 (41.8)
Service sector Private (117) 2625 (86.8) 1124 (77.8) 3749 (83.9)
Local Authority (19) 246 (8.1) 205 (14.2) 451 (10.1)
Third sector (11) 153 (5.1) 115 (8.0) 268 (6.0)
Care-home size Small (41) 417 (13.8) 220 (15.2) 637 (14.3)
Medium (68) 1314 (43.5) 714 (49.4) 2028 (45.4)
                               
                             
                     
Large (37) 1290 (42.7) 510 (35.3) 1800 (40.3)
Missing data (1)
RAD score Low (102) 1994 (65.9) 1045 (72.4) 3039 (68.0)
Medium (19) 421 (13.9) 175 (12.1) 596 (13.3)
High (26) 609 (20.1) 224 (15.5) 833 (18.6)
Health board Tayside (90) 1871 (61.9) 805 (55.7) 2676 (59.9)
Fife (57) 1153 (38.1) 639 (44.3) 1792 (40.1)
1. Distribution normal overall but skewed in groups so SD and IQR not reported for groups. Overall distribution shown in Figure S1
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Table 2. Number of care-home residents, mean number of medicines, and most frequent drug class prescribed, by BNF chapter
BNF Chapter Number (%) Mean (SD) 1st 2nd 3rd 4th 5th









2 Cardiovascular 2883 (64.5) 2.32 (1.3) Statins 
(27.3%)




























Nitrofurantoin (6.2%) Penicillinase resistant 
penicillins (4.2%)
Tetracyclines (4.1%)
6 Endocrine System 1658 (37.1) 1.26 (0.56) Thyroid hormones (19.2%) Bisphosphonates and drugs 
affecting bone metabolism 
(10.1%)
Biguanides (5.3%) Treatment 
corticosteroids (3.4%)
Male sex hormones and 
antagonists (3.3%)
7 Obstetrics, Gynaecology 
& Urinary-Tract Disorder
404 (9.0) 1.07 (0.27) Drugs for urinary frequency, 
enuresis, incontinence 
(5.3%)
Drugs for urinary retention 
(3.4%)





Drugs used in 
urological pain (0.1%)
8 Malignant Disease & 
Immunosuppression
83 (1.9) 1 (0) Hormone antagonists 
(1.5%)





9 Nutrition and Blood 2011 (45.0) 1.98 (0.78) Vitamin D (35.6%) Oral iron 
(10.2%)







                               
                             
                     
10 Musculoskeletal and 
Joint Diseases
692 (15.5) 1.09 (0.31) Rubefacients, topical 
NSAIDs, capsaicin, and 
poultices (11.7%)





Methotrexate (0.4%) Nonselective NSAIDs 
(0.4%)
11 Eye 595 (13.3) 1.46 (0.82) Tear deficiency, ocular 











12 Ear, Nose and 
Oropharynx
133 (3.0) 1.06 (0.24) Nasal allergy, topical 
antihistamines and 
cromoglicate (1.6%)
Drugs for oral ulceration 
and inflammation (0.5%)











Shampoos and other 
preparations for 
scalp/hair (1.7%)
                               
                             
                     
Figure 2. Percentage of care-home residents prescribed drugs associated with eight common ADEs
                               
                             
                     
Table 3. Multilevel logistic regression analysis of excessive polypharmacy in care-home residents







Age Group 60-64 19 (21.8) Ref Ref
65-69 53 (34.4) 1.76 (0.94-3.29) 1.80 (0.96-3.38)
70-74 101 (35.4) 1.79 (1.00-3.21) 1.86 (1.04-3.34)
75-79 163 (34.0) 1.67 (0.96-2.94) 1.73 (0.98-3.03)
80-84 302 (34.2) 1.65 (0.96-2.85) 1.75 (1.01-3.02)
85-89 393 (33.9) 1.60 (0.93-2.75) 1.66 (0.97-2.87)
90-94 288 (28.9) 1.18 (0.68-2.04) 1.19 (0.69-2.07)
≥95 125 (29.4) 1.14 (0.64-2.01) 1.08 (0.61-1.92)
Sex Male 422 (33.2) Ref -
Female 1022 (32.0) 0.89 (0.77-1.03) -
Dementia status No Dementia 802 (34.7) Ref  Ref
Dementia 642 (29.7) 0.78 (0.68-0.89) 0.73 (0.64-0.84)
Care-home type Nursing 743 (28.6)  Ref Ref 
Residential 701 (37.5) 1.49 (1.19-1.85) 1.50 (1.19-1.88)
RAD score3 Low 1045 (34.4)  Ref  Ref
Medium 175 (29.4) 0.75 (0.54-1.06) 0.72 (0.52-0.99)
High 224 (26.9) 0.69 (0.51-0.93) 0.77 (0.56-1.04)
NHS Health Board Tayside 805 (30.1)  Ref  Ref
Fife 639 (35.7) 1.24 (0.99-1.57) 1.37 (1.09-1.71)




1. Number of groups = 147, N in all models = 4468, service sector and care-home size not fitted in models as collinear with care-home status.
2. C-statistic = 0.685. 
3. Risk Assessment Document Quality Score. 
Ref = used as reference. - = variable not fitted
                               
                             
                     
